




# INTRODUCING PERISOLV<sup>®</sup>: BIOFILM-ERASER



Elimination of the biofilm is key for the treatment success of periodontitis, peri-implant mucositis, and peri-implantitis.

**BTC** Speciality Health.




# A NEW MINIMALLY INVASIVE APPLICATION

For periodontal and peri-implant inflammation

Periodontitis, peri-implant mucositis and peri-implantitis are bacterial inflammations with similar symptoms. The underlying cause of all three indications, which progress in a similar way, is bacterial plaque forming a biofilm, rich in pathogenic bacteria. The softening of the biofilm and effective elimination of the bacteria is thus the key prerequisite for effective treatment of these conditions.

Originated from Sweden, PERISOLV® is the first chemo mechanical treatment to be introduced to Australia. It is a new cleaning gel used in addition to mechanical debridement.



## INDICATIONS:

PERISOLV® is indicated for use in:

- ✓ Peri-implantitis
- ✓ Mucositis
- ✓ Periodontitis

# PERISOLV®-EFFECTS


- Elimination of the biofilm\*
- Reduction of pocket depth even in persistent pockets<sup>1,2</sup>

\*Enhancing bacterial removal by mechanical debridement


## Pocket depth reduction, even for persistent pockets<sup>1,2</sup>

Positive in vitro data were also confirmed in a clinical case series study at the University of Ferrara.<sup>1</sup> The periodontal conditions of patients with infected deep residual pockets, a positive BOP and a pocket depth of  $\geq 5$  mm before treatment could be significantly improved after treatment with PERISOLV®. The average pocket depth before treatment was  $5.7 \pm 1.0$  mm, decreasing to  $3.4 \pm 0.5$  mm after treatment with ultrasound and PERISOLV®. After treatment, all pockets had a depth of  $\leq 4$  mm and were BOP-negative.

### Average PPD



### Average pocket depth\*\*



The effect of PERISOLV® on patients with residual pockets was documented via a case series in a private practice in Switzerland.<sup>2</sup> PERISOLV® was used in the treatment of 18 patients (173 residual pockets  $\geq 5$  mm). Follow-up ranged from 9 to over 30 weeks. A reduction in depth was determined in 76% of pockets. It was observed that in 66% of 5 mm pockets (depth from 5 mm to 3.87 mm), in 84% of 6 mm pockets (depth from 6 mm to 4.61 mm) and 92% of 7 mm pockets (depth from 7 mm to 5.62 mm), the probing depth was reduced. All other pockets remained stable. Using PERISOLV® also had a positive effect on BOP. Almost 70% of BOP-positive cases became BOP-negative.

# MODE OF ACTION

Mechanical debridement alone or with PERISOLV®

## Clear syringe with gel

- Water
- Carboxy methylcellulose (CMC)
- Sodium chloride
- Amino acids
- Titanium dioxide
- Alkaline pH

## White syringe with liquid

- Water
- Sodium hypochlorite

PERISOLV®

# TREATMENT OF PERI-IMPLANT MUCOSITIS

Case by Prof. Vincenzo Iorio-Siciliano, University of Catanzaro, Italy



Implant with probing depth (PD)  $\leq$  5mm and BOP<sup>+</sup>



Application of PERISOLV® before non-surgical treatment



Biofilm removal using a sonic scaler with PEEK tip



**6 MONTHS AFTER TREATMENT**  
Probing depth (PD) after 6 months observation time

More clinical cases available at [btchealth.com.au](http://btchealth.com.au)

# TREATMENT OF A FURCATION DEFECT

Case by Prof. Vincenzo-Iorio-Siciliano, University of Catanzaro, Italy




1. A PD of 5 mm was noted
2. A class-II furcation defect was recorded



3. First application of PERISOLV®
4. Scaling was performed using an ultrasonic device




5. Second application of PERISOLV®
6. Root planing was performed




- 6 MONTHS AFTER TREATMENT
7. A PD of 3 mm was reported
8. A class-I furcation defect with BOP was recorded


# SIMPLE APPLICATION




1. CONNECT




2. MIX



3. CANNULA




4. APPLY



30 sec

5. WAIT



Repeat 4-6

6. START REGULAR SCALING





---

## REFERENCES

1. Guarnelli ME et al. 'Professional local administration of chloramine-based treatment in conjunction with ultrasonic mechanical instrumentation: clinical outcomes in patients with deep periodontal pockets persisting following active non-surgical therapy'. *Minerva Stomatologia*, April 2015; Vol. 64 suppl. 1 al No. 2: 158-159.
2. Data on file 2016

PERISOLV® is a registered trademark and is manufactured by RLS Global AB, Neongatan 5, SE-431 53 Mölndal.

PERISOLV® is distributed by BTC Speciality Health Pty Ltd (a wholly owned company of BTC Health) under licence from RLS Global AB.'

**BTC Speciality Health.**

Suite 201, 697 Burke Road, Camberwell VIC 3124, Australia.  
Website: [btchealth.com.au](http://btchealth.com.au), Queries: [queries@btchealth.com.au](mailto:queries@btchealth.com.au),  
Phone No: 1800 100 282 PC: 0082018